The emerging role of lapatinib in HER2-positive breast cancer

Current Oncology Reports

Volumn 10, Issue 1, 2008, Pages 10-17

  Ulhoa Cintra, Alice ^b   Greenberg, Larisa ^b   Geyer, Charles E ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROMYCIN; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PHENOBARBITAL; PIOGLITAZONE; PYRROLE DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DYSPEPSIA; FATIGUE; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 38149058790     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0004-0     Document Type: Review

References (49)

1. Ries LAG, Melbert D, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; based on November 2006 SEER data submission, posted to the SEER website 2007. http://seer.cancer.gov/csr/1975_2004/.
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Berry DA, Cronin KA, Plevritis SK, et al.: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792.
4. Bartsch R, Wenzel C, Zielinski CC, et al.: HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs 2007, 21:69-77.
5. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
6. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001, 344:783-792.
7. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 353:1673-1684.
8. Smith I, Procter M, Gelber R, et al.: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007, 369:29-36.
9. Pazdur R, Keegan P: FDA approval for lapatinib ditosylate. National Cancer Institute website. http://www.cancer.gov/cancertopics/ druginfo/fda-lapatinib. Accessed October 9, 2007.
10. Nelson MH, Dolder CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006, 40:261-269.
11. Witters LM, Witkoski A, Planas-Silva M, et al.: Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-Her-2/neu and a Bcl-2 inhibitor. Oncol Rep 2007, 17:465-469.
12. Quadros MR, Connely S, Kari C, et al.: EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities. Cancer Biol Ther 2006, 5:498-504.
13. Wolff AC, Hammond WE, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
14. Hudis CA: Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
15. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
16. Esteva FJ, Valero V, Booser D, et al.: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:1800-1808.
17. Burstein HJ, Harris LN, Marcom PK, et al.: Trastuzumab and vinorelbine as first-fine therapy for HER2-overexpressing metastatic breast cancer. multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21:2889-2895.
18. Perez EA, Romond EH, Suman VJ, et al.: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [ASCO abstract 512]. J Clin Oncol 2007, 25(18S):512.
19. Slamon D, Eiermann W, Robert N, et al.: BCIRG 006: second interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract 52. Presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 14-17, 2006.
20. Faneyte IF, Peterse JL, Van Tinteren H, et al.: Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004, 10:4457-4463.
21. Mackey J, Gelmon KA, Verma S, et al.: Continued use of Herceptin after disease progression in women with HER2-positive (HER2+) metastatic breast cancer (MBC): results from a retrospective analysis of 105 cases [abstract]. Proc Am Soc Clin Oncol 2002, 21:207.
22. Tripathy D, Slamon DJ, Cobleigh M, et al.: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22:1063-1070.
23. Nahata R, Yu D, Hung MC, et al.: Mechanisms of disease: understanding resistance to Her2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3:269-280.
24. Moulder SL, Yakes FM, Muthuswamy SK, et al.: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001, 61:8887-8895.
25. Saez R, Molina MA, Ramsey EE, et al.: p95Her-2 predicts worse outcomes in patients with HER-2-positive breast cancer. Clin Cancer Res 2006, 12:424-431.
26. Lin NU, Dieras D, Paul D, et al.: EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with Her2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy [ASCO abstract 1012]. J Clin Oncol 2007, 25(18S):1012.
27. Tykerb (lapatinib) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
28. Burris HA III, Hurwitz HI, Dees EC, et al.: Phase I safety, pharmacokinetics and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313.
29. Schwatz G, Chu QS, Hammond LA, et al.: Phase I clinical, biology and pharmacokinetic study of GW 572016 and capecitabine in patients with advanced solid tumors [ASCO abstract 3070]. J Clin Oncol 2004, 22(14S):3070.
30. Storniolo A, Burris H, Pegram M, et al.: A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen [ASCO abstract 559]. J Clin Oncol 2005, 23(16S):559.
31. Blackwell KL, Kaplan EH, Franco SX, et al.: A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens [abstract 103]. Presented at the 29th European Society for Medical Oncology Congress. Vienna, Austria; October 29-November 2, 2004.
32. Burstein H, Storniolo AM, Franco S, et al.: A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens [abstract 104]. Presented at the 29th European Society for Medical Oncology Congress. Vienna, Austria; October 29-November 2, 2004.
33. Gomez HL, Chavez MA, Doval DC, et al.: Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with erbB2-amplified advanced or metastatic breast cancer [abstract 1090]. Presented at the 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX; December 14-17, 2006.
34. Geyer C, Forster J, Lindquist D, et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 356:1487-1502.
35. Di Leo A, Gomez H, Aziz Z, et al.: Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a phase III randomized double-blind study of 580 patients [ASCO abstract 1011]. J Clin Oncol 2007, 25(18S):1011.
36. Geyer CE, Martin A, Newstat B, et al.: Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data [ASCO abstract 1035]. J Clin Oncol 2007, 25(18S):1035.
37. Perez EA, Byrne JA, Hammond IW, et al.: Results of an analysis of cardiac function in 2,812 patients treated with lapatinib [ASCO abstract 583]. J Clin Oncol 2006, 24(18S):583.
38. Chu I, Blackwell K, Chen S, et al.: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005, 65:18-25.
39. A randomized, double-blind, ptacebo-controlled, multi-center, phase III study comparing GW572016 and letrozole versus Letrozole in subjects with estrogen/progesterone receptor-positive advanced or metastatic breast cancer. ClinicalTrials.gov website. http://www.clinicaltrials.gov/ct/show/NCT00073528?order=1. Accessed October 9, 2007.
40. Aragon-Ching JB, Zujewski JA: CNS metastasis: an old problem in a new guide. Clin Cancer Res 2007, 13:1644-1647.
41. Bendell JC, Domchek SM, Burstein HJ, et al.: Central nervous system metastasis in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977.
42. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 2000, 18:2349-2351.
43. A randomized, double blind, placebo-controlled, multi-center, phase III study comparing the activity of paclitaxel plus trastuzumab plus lapatinib to paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer. ClinicalTrials.gov website. http://www.clinicaltrials.gov/ct/show/NCT00272987?order=1. Accessed October 9, 2007.
44. Endocrine therapy with or without inhibition of EGF and HER2 growth factor receptors: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib (GW572016) for postmenopausal women with hormone receptor positive advanced breast cancer. ClinicalTrials.gov website. http://www.clinicaltrials.gov/ct/ show/NCT00390455?order=1. Accessed October 9,2007.
45. A randomized phase III trial of ncoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following AC accompanied by correlative science studies to identify predictors of pathologic complete response. ClinicalTrials.gov website. http://clinicaltrials.gov/ct/show/ NCT00486668;jsessionid=34B8BC9FBBC2BBC58D240AE61AF2A726?order=33. Accessed October 9, 2007.
46. Eidtmann H, Di Cosimo S, Gelber R, et al.: Neo-ALTTO: neo-adjuvant lapatinib and/or trastuzumab treatment optimisation study (BIG 1-06/ EGF106903). Breast International Group Newsletter 2007, 9:11-13. http://www.breastinternationalgroup.org/downloads/ ~rchive/9fab23b8-fcc7-42f8-9690-b12l96b1bb59.pdf. Accessed October 9, 2007.
47. Enos R: Collaboration Big - North American Breast Cancer Cooperative Groups. Breast International Group Newsletter 2007, 9:20. http://www.breastinternationalgroup.org/downloads/archive/ 9fab23b8-fcc7-42f8-9690-b12196b1bb59.pdf. Accessed October 9, 2007.
48. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. ClinicalTrials.gov website. http://clinicaltrials.gov/show/NCT00490139. Accessed October 9,2007.
49. A randomized, double-blind, multicenter, placebo-controlled study of adjuvant lapatinib (GW572016) in women with Early-stage ErbB2 overexpressing breast cancer. ClinicalTrials.gov website. http://www.clinicaltrials.gov/ct/show/NCT00374322?order=27. Accessed October 9, 2007.